Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04094636
Other study ID # CAP-EX
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 1, 2019
Est. completion date October 1, 2022

Study information

Verified date February 2022
Source Nordsjaellands Hospital
Contact Camilla Ryrsø, MSc
Phone +4548293261
Email camilla.koch.ryrsoe.01@regionh.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the effect of standard usual care combined with daily supervised physical training during hospitalization with community-acquired pneumonia (CAP) compared to standard usual care alnone.


Description:

Community-acuired pneumonia (CAP) is a leading cause of hospitalization worldwide. Despite increased focus on mobilization, hospitalization is associated with bed rest. Bed rest with low levels of physical activity leads to functional deline as well as increased risk of complications. This study is a randomized controlled trial, which investigates the effect of standard usual care combined with daily supervised physical training in patients hospitalized with CAP compared to standard usual care alone.


Recruitment information / eligibility

Status Recruiting
Enrollment 210
Est. completion date October 1, 2022
Est. primary completion date April 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients 18 years of age or older admitted to hospital with CAP defined as a new infiltrate on chest X-ray/CT and minimum one of the following symptoms: temperature <35°C or =38°C, cough, pleuritic chest pain, dyspnea, or focal chest signs on auscultation. - Patients should have an expected admission length of =72 hours. - Patients should be able to move their legs. Exclusion Criteria: - Patients unable to give written consent. - Hospital admission within the last 14 days. - Severe immunosuppression (cancer chemotherapy =28 days, neutropenia =1000 cells/µL, =20 mg prednisolone-equivalent/day >14 days or other immunosuppressive drugs, HIV infection, former transplant).

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
In-bed cycling
Patients will daily perform 30 min of supervised in-bed cycling
Exercise booklet
Patients will daily perform 30 min of supervised physical training with exercises from the exercise booklet

Locations

Country Name City State
Denmark Department of Pulmonary and Infectious Diseases, Nordsjællands Hospital Hillerød

Sponsors (1)

Lead Sponsor Collaborator
Nordsjaellands Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Self-reported physical activity (PA) level 3 groups of PA level (high, medium, low) are established based on the scoring of the international physical activity questionnaire (IPAQ).
High PA level: Vigorous-intensity activity on at least 3 days and accumulating a minimum of 1500 MET-minutes/week OR 7 or more days of any combination of walking, moderate-intensity or vigorous intensity activities achieving a minimum of 3000 MET-minutes/week
Medium PA level: 3 or more days of vigorous-activity of at least 20 minutes/day OR 5 or more days of moderate-intensity activity or walking of at least 30 minutes/day OR 5 or more days of any combination of walking, moderate-intensity or vigorous-intensity activities achieving a minimum of 600 MET-min/week.
Low PA Level: No activity is reported OR some activity is reported but not enough to meet criteria for high or medium PA level group.
Answered on day 1, 1-, 3- and 6 months after discharge
Other Glucose metabolism Blood samples drawn during an oral glucose tolerance test Day 1, 1- and 3-months from discharge
Other Scoring on the Charlson Comorbidity Index to predict 10-year survival Scale ranges from 0 to 33 points to predict he 10-year mortality for patients with a range of comorbid conditions Day 1
Other HbA1c To assess the average blood glucose levels over the previous 3 months Day 1, 1- and 3-months after discharge
Primary Length of hospital stay Number of stays in hospital From admission until discharge (an average of 5 days)
Secondary Readmissions Number of readmissions Time-to-event within 3-months from discharge 3-months from discharge
Secondary Mortality Time-to-event within 6-months from discharge 6-months from discharge
Secondary Changes in total lean mass Dual-energy x-ray absorptiometry scans Day 1, day 5, discharge, 1- and 3-months from discharge
Secondary Changes in total fat mass Dual-energy x-ray absorptiometry scans Day 1, day 5, discharge, 1- and 3-months from discharge
Secondary Changes in total fat-free mass Bioelectrical impedance analysis Day 1, day 5, discharge, 1- and 3-months from discharge
Secondary Health-related quality of life Scoring from -0.624 to 1.000 on the 5-level EQ-5D version (EQ-5D-5L) questionnaire (Danish version), with higher score indicating better health-related quality of life Day 1, discharge, 1-, 3- and 6-months from discharge
Secondary Activities of daily living Scoring from 0 to 100 on the Barthel Index for Activities of Daily Living (ADL) with higher score indicating greater independence. Day 1, discharge, 1 month from discharge and 3 months from discharge
Secondary Muscle strength Hand grip strength test At day 1, day 5, discharge, 1- and 3-months after discharge
Secondary Functional ability 30-sec chair stand test Day 1, day 5, discharge, 1- and 3-months after discharge
Secondary Systemic inflammation Pro- and anti-inflammatory cytokine concentrations measured in pg/ml (IL-6, IL-8, IL-18, IL-1a, IL-10, TNF-alpha) Daily during admission (day 0 to 5), 1- and 3-months after discharge
Secondary Physical activity monitoring AX3 accelerometers During admission (up to 7 days), 7 days from discharge, 7 days from 1- and 3 months follow-up
See also
  Status Clinical Trial Phase
Recruiting NCT05722938 - Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP) Phase 3
Terminated NCT04972318 - Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia N/A
Recruiting NCT06065618 - Characteristics of Hospitalized Patients With Community-acquired Pneumonia
Not yet recruiting NCT03675178 - Clinical Study of Anerning Particle for the Treatment of Childhood Community-acquired Pneumonia Phase 4
Not yet recruiting NCT04166110 - Antibiotic Therapy In Respiratory Tract Infections N/A
Completed NCT02380352 - Short-course Antimicrobial Therapy for Paediatric Respiratory Infections Phase 4
Completed NCT01671280 - Drug Use Investigation Of Azithromycin IV For Community-Acquired Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan) N/A
Completed NCT02555852 - Proton Pump Inhibitors and Risk of Community-acquired Pneumonia N/A
Recruiting NCT00752947 - Efficacy and Safety Trial to Assess Moxifloxacin in Treating Community-Acquired Pneumonia (CAP) With Aspiration Factors Phase 4
Completed NCT00140023 - Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia Phase 3
Recruiting NCT04089787 - Shortened Antibiotic Treatment of 5 Days in Community-Acquired Pneumonia Phase 4
Completed NCT05356494 - Postural Drainage and PEP Technique in Community Acquired Pneumonia N/A
Completed NCT05133752 - Oral Nemonoxacin in Treating Elderly Patients With CAP Phase 4
Not yet recruiting NCT06291012 - Stopping Pneumonia Antibiotherapy Regimen Early Phase 4
Recruiting NCT05002192 - A Retrospective, Real-world Study of ELP Used in the Expectorant Treatment of Community-acquired Pneumonia
Completed NCT03452826 - Combined Use of a Respiratory Broad Panel mPCR and Procalcitonin to Reduce Duration of Antibiotics Exposure in Patients With Severe Community-Acquired Pneumonia N/A
Terminated NCT04071041 - Effect of Albumin Administration in Hypoalbuminemic Hospitalized Patients With Community-acquired Pneumonia. Phase 3
Completed NCT03474991 - KIDS-STEP_Betamethasone Therapy in Hospitalised Children With CAP Phase 3
Completed NCT01723644 - Clinical Reassessment Versus Procalcitonin in Order to Shorten Antibiotic Duration in Community-acquired Pneumonia N/A
Withdrawn NCT01662258 - Microbiology Testing With the Aim Of Directed Antimicrobial Therapy For CAP N/A